Active ingredientEncorafenibCat. No. P-E045-001CAS 1269440-17-6Family · Pharmaceutical analytical standards
Encorafenib
An oral anticancer drug that blocks mutated BRAF protein: it is used for melanoma with a BRAF V600 mutation and, since 2020 in the United States, with cetuximab for metastatic colorectal cancer with the BRAF V600E mutation. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?The code V600E means that in the BRAF protein the amino acid valine at position 600 is replaced by glutamic acid: a single change that keeps the cell's growth signal permanently switched on.
Go to the active ingredient →Active ingredientEncorafenibCat. No. P-E045-001CAS 1269440-17-6
Isotopically labelledEncorafenib-d7Cat. No. P-E045-002CAS 2413673-15-9
ImpurityEncorafenib Impurity 1Cat. No. P-E045-003CAS 1934917-37-9
ImpurityEncorafenib Impurity 2Cat. No. P-E045-004CAS 2285221-21-6
ImpurityEncorafenib Impurity 3Cat. No. P-E045-005CAS 1269440-58-5
ImpurityEncorafenib Impurity 4Cat. No. P-E045-006CAS 1269440-54-1
ImpurityEncorafenib R-IsomerCat. No. P-E045-007CAS 1269440-29-0![Methyl N-[(2S)-2-aminopropyl]carbamate](https://img.vitasanlabs.com/vsl-struct/P-E045-008.svg?v=41e934f030)
ImpurityMethyl N-[(2S)-2-aminopropyl]carbamateCat. No. P-E045-008CAS 1672679-77-4
ImpurityEncorafenib Impurity 5Cat. No. P-E045-009CAS 2148445-66-1
ImpurityEncorafenib Impurity 6Cat. No. P-E045-010CAS 2409597-16-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.